ReiThera, an Italy-based biotech company, announced on Thursday that it has received operational authorisation from the Italian Medicines Agency (AIFA) to open the new production area at its pharmaceutical facility based in the Castel Romano Technopole.
The facility was set up for the large-scale production of viral vectors for vaccines and gene therapy. According to ReiThera it provides maximum flexibility in processing scale, able to accommodate GMP productions based on Adenovirus (Ad), Adeno-associated virus (AAV) and Lentivirus, starting from 50 litres up to a maximum of 3,000 litres.
Construction of the new production facility began in May 2020 with an investment of over EUR15m euros by ReiThera. This investment enabled the installation of the latest generation bioreactors with scaled volume capacities of 200, 1,000 and 2,000 litres.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma